• Bolsters Prenetics’ pro-forma cash reserves to approximately US$86 million, and pro-forma cash and short-term assets to approximately US$117 million
   
• Prenetics simplifies investment thesis as company focuses on high-growth consumer health brands IM8, CircleDNA, and Europa
   
• Prenetics raised its FY2025 outlook to be US$80 – US$100 million from $73 – US$85 million, driven by the growth of IM8

CHARLOTTE, N.C., June 18, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics”), a leading consumer health sciences company, today announced it has entered into a definitive agreement to divest its ownership in ACT Genomics Holdings Company Limited (“ACT Genomics”) to Delta Electronics, Inc. (TWSE: 2308) (“Delta”). Delta is a global leader in power management and smart green solutions, as well as a provider of healthcare technologies. The transaction regarding Delta’s acquisition of up to 100% ACT Genomics’ shareholdings is valued at up to US$71.78 million. Prenetics, holding a majority stake in ACT Genomics, will receive a gross proceed of approximately US$46 million in cash post-closing of the transaction and subject to customary release conditions. With a cash balance of US$44 million¹, this divestment bolsters Prenetics financial position, increasing its pro-forma cash reserves to approximately US$86 million² and with $117 million pro-forma short term assets³, while maintaining a debt-free balance sheet.

ACT Genomics’ expertise in clinical diagnostics and next-generation sequencing (NGS) is expected to complement Delta’s existing healthcare solutions portfolio, fostering new synergies and growth opportunities in the precision medicine market.

Danny Yeung, CEO and Co-Founder of Prenetics, commented, “This transaction is a testament to the value we have built within ACT Genomics and marks an important milestone for Prenetics. We are incredibly proud of the ACT Genomics team and their contributions. We are confident that under Delta’s stewardship, ACT Genomics will continue to thrive and make significant contributions to the field of genomic medicine.”

Strategic Transformation: Simplified Business Model with Exceptional Growth

The divestment of ACT Genomics marks the successful completion of Prenetics' strategic transformation, addressing previous investor feedback regarding business complexity while positioning the company for accelerated growth in the high-margin consumer health market. The transaction enables Prenetics to simplify its investment thesis, enhance financial flexibility, accelerate growth focus, and optimize resource allocation.

Exceptional Consumer Health Performance Validates Strategy: Prenetics' consumer health business has demonstrated remarkable momentum with:

• Q1 2025 revenue of $14.4 million representing a 336.5% increase year-over-year
   
• Management increased full-year 2025 revenue guidance to US$80-100 million (excluding ACT Genomics), up from the previous range of US$73-85 million, demonstrating confidence in the core business trajectory.

IM8 Health Success Story: The flagship IM8 brand, has achieved extraordinary success in just six months since launch with:

• Over 55,000 customers acquired, 4.9 million servings delivered
   
• Industry-leading 91% subscription rate, US$109 average order value,
   
• Global expansion to 31 countries
   
• Q1 revenue of US$5.7 million and projected Q2 revenue of US$8.5 million (50% quarter-over-quarter growth).

Focused Portfolio of Leading Consumer Health Brands: Post-divestment, Prenetics operates three complementary consumer health brands: IM8 (premium health supplements brand), CircleDNA (leading direct-to-consumer DNA testing platform), and Europa (one of the largest sports nutrition distribution companies in the United States).

Enhanced Financial Position Enables Significant Opportunities for Shareholder Value

The ACT Genomics divestment significantly strengthens Prenetics' financial foundation with pro-forma cash reserves of approximately US$86 million and pro-forma cash and short−term assets of US$117 million. The company maintains its debt-free balance sheet with zero debt.

Strategic Investment Portfolio: Beyond its operating businesses, Prenetics maintains a valuable 35% stake in Insighta, an early cancer detection company. Based on Tencent's recent investment in Insighta, this stake is valued at $70 million, representing significant additional value for Prenetics shareholders.

Innovation Leadership: With a robust cash position and accelerating business fundamentals, Prenetics is strategically positioned to explore cutting-edge treasury management approaches, including digital asset adoption and Bitcoin treasury strategies.

"Today marks a defining moment for Prenetics," said Danny Yeung, CEO and Co-Founder of Prenetics. "We have successfully transformed from a complex, multi-segment company into a focused, high-growth consumer health leader with an exceptionally strong balance sheet. Our investors now have a clear, simple story: three proven consumer health brands, accelerating growth, and substantial financial resources."

"With IM8's remarkable success, CircleDNA's established market position, and Europa's distribution expertise, we have all the components needed to build a leading global consumer health company. The ACT Genomics divestment provides us with the financial resources and management focus to execute this vision. Additionally, our strong cash position enables us to explore innovative crypto and bitcoin treasury management strategies that will be announced shortly, further demonstrating our commitment to maximizing shareholder value through both operational excellence and forward-thinking capital allocation."